Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million
Analysts expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to report $6.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for CymaBay Therapeutics’ earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $10.00 million. The firm is scheduled to announce its next earnings report on Thursday, March 22nd.
According to Zacks, analysts expect that CymaBay Therapeutics will report full-year sales of $6.75 million for the current fiscal year, with estimates ranging from $4.80 million to $14.79 million. For the next financial year, analysts anticipate that the firm will report sales of $0.00 per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same quarter last year, the business earned ($0.25) earnings per share.
In other news, SVP Charles Mcwherter acquired 5,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were purchased at an average price of $8.67 per share, for a total transaction of $43,350.00. Following the transaction, the senior vice president now directly owns 10,300 shares of the company’s stock, valued at $89,301. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kurt Von Emster sold 108,876 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The disclosure for this sale can be found here. Insiders have sold a total of 447,257 shares of company stock worth $3,730,862 in the last quarter. Company insiders own 15.10% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Ardsley Advisory Partners increased its position in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 20,000 shares during the period. EAM Investors LLC bought a new position in shares of CymaBay Therapeutics in the third quarter worth $4,788,000. Omega Fund Management LLC increased its position in shares of CymaBay Therapeutics by 82.9% in the third quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after purchasing an additional 250,000 shares during the period. Vanguard Group Inc. increased its position in shares of CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares during the period. Finally, Marshall Wace North America L.P. bought a new position in shares of CymaBay Therapeutics in the second quarter worth $242,000. Hedge funds and other institutional investors own 68.77% of the company’s stock.
Shares of CymaBay Therapeutics (CBAY) traded up $0.05 during trading on Friday, reaching $8.71. The company’s stock had a trading volume of 573,250 shares, compared to its average volume of 536,157. CymaBay Therapeutics has a fifty-two week low of $1.46 and a fifty-two week high of $9.40. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.